News Releases

Monday, May 02, 2016

UH Seidman Cancer Center first in the world to apply SBRT to partial prostate gland for prostate cancer

CLEVELAND– University Hospitals Seidman Cancer Center physicians have started the world’s first clinical trial using a new form of stereotactic body radiotherapy (SBRT) to deliver radiation to a specific area of the prostate invaded with cancer – instead of the entire gland. The study aims to determine if treating a targeted cancer region within the prostate in early stage prostate cancer can increase treatment options and reduce the side effects of radiation.
If successful, the trial could have a significant impact on the standard of care for men diagnosed with low or intermediate risk prostate cancer.
The trial’s first patient was enrolled and underwent therapy earlier this month without any side effects reported to date. The procedure was performed jointly by his urologist, Lee Ponsky, MD, of the UH Urology Institute and a study co-investigator, and his radiation oncologist Rodney Ellis, MD.

Thursday, April 21, 2016

Two Case Western Reserve University faculty members inducted into prestigious medical honor society

CLEVELAND –  Two members of the faculty of Case Western Reserve University School of Medicine, Drs. Derek Abbott and Goutham Narla, have been inducted into the American Society for Clinical Investigation (ASCI), one of the nation’s oldest and most prestigious medical honor societies for physician-scientists. ASCI emphasizes translating findings in the laboratory to the advancement of clinical practice.

Election to the Society reflects a major early-to-mid-career achievement since new members must be 50 years of age or younger. The 2016 Case Western inductees are:

Derek Abbott, MD, PhD, the Arline H. and Curtis F. Garvin Professor of Medicine; Dr. Abbott was elected for his work combining molecular, bioinformatic, and proteomic approaches to identify and pharmaceutically target novel inflammatory signaling pathways. Cell signaling governs basic cellular activities and coordinates cell actions. Disturbance or errors within this communication chain can lead to various diseases and cancers. Better understanding of cell signaling can lead to more effective treatment of diseases.

Goutham Narla, MD, PhD, assistant professor, Case Western Institute for Transformative Molecular Medicine and Pardee-Gerstacker Professor in Cancer Research at the School of Medicine. He also is a University Hospitals Harrington Discovery Institute Distinguished Scholar (early career award), as well as a medical geneticist at UH Case Medical Center, specializing in the care of high risk cancer patients. Dr. Narla was elected for his contributions to an understanding of novel mechanisms of tumor suppressor gene inactivation. His work includes the development of strategies to reactivate tumor suppressor gene function for treating human cancer. 

Monday, April 18, 2016

University Hospitals Case Medical Center first surgical site to test regenerative treatment for chronic stroke

CLEVELAND – University Hospitals Case Medical Center is the first surgical site for a Phase 2b clinical trial study to further evaluate the safety and efficacy of an investigational cell therapy for the treatment of chronic motor deficit following an ischemic stroke.
“With strokes, focus has been on prevention or treatment within the first few hours,” said Jonathan Miller, MD, Director of the Center for Functional and Restorative Neurosurgery at UH Case Medical Center, who performs the stem cell surgery as part of the study.  “Stroke is the leading cause of adult disability in the U.S., and there really hasn’t been much for this patient population.” 

Ischemic strokes account for approximately 87 percent of all strokes in the US and occur when there is an obstruction in a blood vessel supplying oxygen to the brain. With approximately 800,000 strokes occurring in the United States every year, stroke is the leading cause of acquired disability in the United States. Traditional stroke treatments generally show little or no improvement in patients after the first six months following a stroke.

Monday, April 18, 2016

University Hospitals Case Medical Center Taps Velano Vascular Technology for Needleless Venous Blood Collection

CLEVELAND – University Hospitals (UH) today announced a collaboration with medical technology company Velano Vascular to use its PIVO needleless device for painless, high quality inpatient venous blood draws. The new device’s breakthrough approach to peripheral intravenous catheter (PIV) blood draws will be launched initially at UH Case Medical Center in the Telemetry and Cardiac Intensive Care units, representing the first major U.S. academic medical center to commercially adopt Velano’s innovation with the aim to establish a new standard of care.
“Within a hospital setting, the blood draw is one of the most common yet most critical aspects of patient care,” said Cheryl O’Malley, Vice President of Medical-Surgical Service, UH Case Medical Center. “Blood collection practices and technologies have not materially changed in decades, making it an area ripe for innovation. We are excited to explore the potential for pain and stress-free inpatient venous blood draws for patients and practitioners alike, and believe the Velano technology holds enormous potential for both patient experience and improved healing.”

Monday, April 18, 2016

Nominations now open for 4th annual Harrington Prize for Innovation in Medicine

CLEVELAND (April 19, 2016)  – National and international nominations are being sought for the fourth annual Harrington Prize for Innovation in Medicine, which honors a physician-scientist for notable achievements in drug research and development that demonstrate innovation, creativity and the potential for clinical application. 
Deadline for nominations is August 29, 2016.
Nomination guidelines can be found at:
The Harrington Prize, which carries a $20,000 honorarium, is a collaboration between The American Society for Clinical Investigation (ASCI), one of the nation’s oldest and most respected medical honor societies, and the Harrington Discovery Institute at University Hospitals in Cleveland, Ohio – part of The Harrington Project for Discovery & Development. The Harrington Discovery Institute is a nonprofit institute dedicated to supporting physician-scientists in their work to transform bench discoveries into promising leads that may result in novel therapeutics. 

You must be logged in to view this item.


This area is reserved for members of the news media. If you qualify, please update your user profile and check the box marked "Check here to register as an accredited member of the news media". Please include any notes in the "Supporting information for media credentials" box. We will notify you of your status via e-mail in one business day.